Greeting from CEO
Young Woo Park
Y-Biologics is a biotechnology company focused on the discovery of antibody therapeutics with proprietary platform technologies. We have secured own fully human antibody library,
Ymax®-ABL (See more) , with phage display technology and have generated several antibody pipelines in various modalities. Furthermore, we have developed novel T cell bispecific antibody platform technology, ALiCE (Antibody Like Cell Engager) which has potential to address current unmet needs in fields of immuno-oncology.
As a reliable service provider, Y-Biologics will guide your journey for generating antibodies with high quality. We keep trying to pursue the best results by fully utilizing our techniques and resources to complete the client’s projects. Besides, we offer bespoke services based on the purpose of research and specific requests of the clients.
To learn more about Y-Biologics, visit our company website:
Constructed fully human antibody library platform
- Fully human antibody library platform
- Protein production platform using mammalian cells
Verification
for immuno-oncology therapeutics
- Discovered human anti PD-1 and PD-L1 antibody
- Confirmed quality of fully human antibody library by securing various pipelines of immuno-oncology therapeutics
- Raised $1.2 million
- Development of novel T cell bispecific antibody platform technology (ALiCE)
- Raised additional investment of $3.1 million
- Licensing out
- Preparation of listing
- Completion of listing
- Entering clinical trials of 2-3 T cell bispecific antibody pipelines
Constructed fully human antibody library platform
- Fully human antibody library platform
- Protein production platform using mammalian cells
Verification
for immuno-oncology therapeutics
- Discovered human anti PD-1 and PD-L1 antibody
- Confirmed quality of fully human antibody library by securing various pipelines of immuno-oncology therapeutics
- Attracted $1.2 million investment
- Development of novel T cell bispecific antibody platform technology (ALiCETM)
- Attracted additional investment $3.1 million
- Licensing out
- Preparation of listing
- Completion of listing
- Entering clinical trials of 2-3 T cell bispecific antibody pipelines